Iterum Therapeutics (ITRM) Stock Analysis

What Iterum Therapeutics does

Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland.

Key metrics

ETFs linked to ITRM

Broad-market and Healthcare sector ETFs an investor holding Iterum Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ITRM fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Iterum Therapeutics?

Iterum Therapeutics trades under the ticker ITRM on NASDAQ.

Which exchange is ITRM listed on?

ITRM is listed on NASDAQ.

What sector does Iterum Therapeutics operate in?

Iterum Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ITRM in a portfolio?

PortView shows ITRM's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.